Cargando…

Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial

BACKGROUND: Pollen extracts and chemically modified allergoids are used successfully in allergen immunotherapy (AIT). Recombinant extracts offer potential advantages with respect to pharmaceutical quality, standardization and dosing. A hypoallergenic recombinant folding variant of the major birch po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klimek, Ludger, Bachert, Claus, Lukat, Karl-Friedrich, Pfaar, Oliver, Meyer, Hanns, Narkus, Annemie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553934/ https://www.ncbi.nlm.nih.gov/pubmed/26328056 http://dx.doi.org/10.1186/s13601-015-0071-x

Ejemplares similares

NMR resonance assignments of a hypoallergenic isoform of the major birch pollen allergen Bet v 1
por: Ahammer, Linda, et al.
Publicado: (2017)

Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms
por: Campana, Raffaela, et al.
Publicado: (2018)

Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy
Publicado: (1996)

Frequent occurrence of T cell–mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments
por: Campana, Raffaela, et al.
Publicado: (2015)

The History and Science of the Major Birch Pollen Allergen Bet v 1
por: Breiteneder, Heimo, et al.
Publicado: (2023)

The Major Birch Pollen Allergen Bet v 1 Induces Different Responses in Dendritic Cells of Birch Pollen Allergic and Healthy Individuals
por: Smole, Ursula, et al.
Publicado: (2015)

Prophylactic and Therapeutic Effects of Oral Immunotherapy on Birch Pollen-Induced Allergic Conjunctivitis in Mice with a Rice-Based Edible Vaccine Expressing a Hypoallergenic Birch Pollen Allergen
por: Ishida, Waka, et al.
Publicado: (2021)

Ligand Recognition of the Major Birch Pollen Allergen Bet v 1 is Isoform Dependent
por: Seutter von Loetzen, Christian, et al.
Publicado: (2015)

Dynamics Rationalize Proteolytic Susceptibility of the Major Birch Pollen Allergen Bet v 1
por: Kamenik, Anna S., et al.
Publicado: (2020)

High-Yield Production of the Major Birch Pollen Allergen Bet v 1 With Allergen Immunogenicity in Nicotiana benthamiana
por: Yamada, Yuki, et al.
Publicado: (2020)

Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1
por: Akinfenwa, Oluwatoyin, et al.
Publicado: (2021)

The Impact of Nitration on the Structure and Immunogenicity of the Major Birch Pollen Allergen Bet v 1.0101
por: Ackaert, Chloé, et al.
Publicado: (2014)

Stabilization of the Dimeric Birch Pollen Allergen Bet v 1 Impacts Its Immunological Properties
por: Kofler, Stefan, et al.
Publicado: (2014)

Pru du 1, the Bet v 1‐homologue from almond, is a major allergen in patients with birch pollen associated almond allergy
por: Kabasser, Stefan, et al.
Publicado: (2022)

Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma
por: Wahn, Ulrich, et al.
Publicado: (2018)

The placebo effect in allergen-specific immunotherapy trials
por: Narkus, Annemie, et al.
Publicado: (2013)

A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations
por: Klimek, Ludger, et al.
Publicado: (2014)

Binding to Iron Quercetin Complexes Increases the Antioxidant Capacity of the Major Birch Pollen Allergen Bet v 1 and Reduces Its Allergenicity
por: Regner, Andreas, et al.
Publicado: (2022)

Prevention of Birch Pollen-Related Food Allergy by Mucosal Treatment with Multi-Allergen-Chimers in Mice
por: Hoflehner, Elisabeth, et al.
Publicado: (2012)

Identification of apple cultivars hypoallergenic for birch pollen‐allergic individuals by a multidisciplinary in vitro and in vivo approach
por: Strobl, Maria R., et al.
Publicado: (2022)

Chinese Birch Pollen Allergy and Immunotherapy in Mice
por: Xie, Zhijuan, et al.
Publicado: (2019)

Seven different genes encode a diverse mixture of isoforms of Bet v 1, the major birch pollen allergen
por: Schenk, Martijn F, et al.
Publicado: (2006)

Nitration of the Birch Pollen Allergen Bet v 1.0101: Efficiency and Site-Selectivity of Liquid and Gaseous Nitrating Agents
por: Reinmuth-Selzle, Kathrin, et al.
Publicado: (2014)

Allergen‐specific immunotherapy with apples: selected cultivars could be a promising tool for birch pollen allergy
por: Nothegger, B., et al.
Publicado: (2020)

Profiles of Birch Allergen Component Sensitization and Its Association with Pollen Food Allergy Syndrome in Northern China
por: Wang, Xiaoyan, et al.
Publicado: (2023)

Trimolecular complex between major birch pollen allergen, Bet v 1, monoclonal allergen-specific human IgE and recombinant CD23
por: Selb, Regina, et al.
Publicado: (2014)

Random mutagenesis and phage display technology as a tool for identifying ige epitopes of the birch pollen allergen Bet v 1
por: Guhsl, Elisabeth Eva, et al.
Publicado: (2014)

Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG(1) and IgG(4) against the Major Birch Pollen Allergen Bet v 1
por: Köhler, Verena K., et al.
Publicado: (2020)

First evaluation of a symbiotic food supplement in an allergen exposure chamber in birch pollen allergic patients
por: Bergmann, Karl-Christian, et al.
Publicado: (2020)

How allergenic are hypoallergenic formulae in patients with severe cow’s milk protein allergy?
por: Claver, Angela, et al.
Publicado: (2011)

Chimeras of Bet v 1 and Api g 1 reveal heterogeneous IgE responses in patients with birch pollen allergy
por: Gepp, Barbara, et al.
Publicado: (2014)

Evaluation of subcutaneous immunotherapy with birch pollen extract for pollen-food allergy syndrome
por: Hamada, Masaaki, et al.
Publicado: (2021)

A high‐dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio
por: Pfaar, Oliver, et al.
Publicado: (2023)

Crystallographically Mapped Ligand Binding Differs in High and Low IgE Binding Isoforms of Birch Pollen Allergen Bet v 1
por: Kofler, Stefan, et al.
Publicado: (2012)

Immunoglobulin E and G4 epitopes of the major allergen of birch pollen Bet v 1 share residues critical for antibody binding
por: Groh, N, et al.
Publicado: (2013)

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy
por: Focke-Tejkl, Margarete, et al.
Publicado: (2015)

Nonpharmacological measures to prevent allergic symptoms in pollen allergy: A critical review
por: Bergmann, Karl-Christian, et al.
Publicado: (2021)

Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy
por: Marth, Katharina, et al.
Publicado: (2014)

High‐affinity Bet v 1‐specific secretory IgA antibodies in nasal fluids protect against birch pollen allergy
por: Huber, Sara, et al.
Publicado: (2021)

High Environmental Ozone Levels Lead to Enhanced Allergenicity of Birch Pollen
por: Beck, Isabelle, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8omr914o9lcm1d39cr92d0opgi